Trial Profile
A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs CHR 5154 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 18 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Sep 2013 New trial record